Metabolic tumor volume on 18F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation
MTV is a significant marker for predicting outcomes after osimertinib monotherapy in patients with advanced NSCLC harboring <i>EGFR</i> mutations.
Authors
- Atsuto Mouri
- Ou Yamaguchi (ORCID: https://orcid.org/0000-0001-7194-6459)
- Hiroshi Kagamu
- I. Kuji
- Hisao Imai
- Kosuke Hashimoto
- Kyoichi Kaira
Institutions
- Saitama Medical University (JP)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-787
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00